paracetamol
File photo of paracetamol | Commons
Text Size:

New Delhi: All 1,600 people who will participate in the trial for the Covid-19 vaccine candidate developed by the Oxford University will be given paracetamol after the vaccine dosage on an ‘SOS’ basis, ThePrint has learnt.

The Pune-based Serum Institute of India (SII) has partnered with Oxford University for the production of the vaccine candidate called Covishield, and will be spearheading these human trials.

The decision to use paracetamol was made at a meeting called by the subject expert committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) Friday.

“Paracetamol shall be given to the trial participants post dosing on SOS basis,” read the minutes of the meeting, accessed by ThePrint.

According to a study in the prominent medical journal, The Lancet, the prophylactic or preventive use of antipyretic drugs such as paracetamol are “recommended to allay concerns of high fever and febrile convulsion (seizures due to fever)”.

The study also found that even though febrile (or fever) reactions “significantly decreased” on prophylactic administration of these antipyretic drugs at the time of vaccination, these should not be “routinely recommended since antibody responses to several vaccine antigens were reduced”.

The Drug Controller General of India (DCGI), India’s apex regulator of clinical trials, approved human trials of Covishield Sunday, based on the recommendations of the SEC meeting Friday.

According to the minutes, the company had also noted that “the market authorization of the vaccine will be based on clinical data generated in the said trial as well as the data from other countries, as available”.

SII has a tie-up with Swedish-British pharmaceutical giant AstraZeneca for the Oxford vaccine. The company is expected to manufacture a billion doses for low- and middle-income countries by 2021.


Also read: Modi govt planning Covid vaccine rollout, says ex-IAS officer who led immunisation programme


Clinical trials to start soon

The CDSCO, which is led by the DCGI, has allowed the trial on 1,600 participants in India, which will take place in over 20 selected sites. The decision to allow trials is based on the data submitted by the SII on Phase 1 and 2 of the clinical trials by the Oxford University.

“Each participant will be given two doses of vaccine four weeks apart to assess the safety and immunogenicity on the defined intervals. The first dose will be given on day one and second dose on day 29,” said a senior government official.

Immunogenicity means the ability of a foreign substance to provoke the body and create an immune response.

The Oxford vaccine candidate is among the frontrunners in the race to develop an effective vaccine against Covid-19.

On 28 July, the SEC had deferred the decision on SII’s proposal to begin human trials in India and had asked the company to rework eight points on the proposal submitted.

However, SII had revised its proposal “within hours”, which led the CDSCO to call up an urgent meeting of the SEC Friday.


Also read: In the race to securing Covid vaccine supplies, rich countries are first in line


The revised protocol

In the final proposal submitted by the SII, it added “five more trial sites in different parts of the country, taking the total to around 20 cites pan India to conduct trials”, a government official had told ThePrint earlier.

It had also attached a memorandum of understanding, as instructed, signed with India’s apex health research body, the Indian Council of Medical Research (ICMR),

“It is about the clauses on the funding of clinical trials and the expenditure ICMR will bear,” the official added.

According to the minutes of the SEC meeting held on 28 July, the panel had asked SII to “demarcate the phase II and phase III part of the protocol”. It had also asked the company that the trial sites proposed for the study should be “distributed across pan India”.

SII was also instructed that the dropout rate of 41 per cent should be revised to keep the rate at par with other vaccine studies.

Furthermore, the SEC had informed the firm that “immunogenicity shall be either primary or secondary objective”.


Also read: Why in this race to Covid-19 vaccine the world will need more than one winner


 

Subscribe to our channels on YouTube & Telegram

Why news media is in crisis & How you can fix it

You are reading this because you value good, intelligent and objective journalism. We thank you for your time and your trust.

You also know that the news media is facing an unprecedented crisis. It is likely that you are also hearing of the brutal layoffs and pay-cuts hitting the industry. There are many reasons why the media’s economics is broken. But a big one is that good people are not yet paying enough for good journalism.

We have a newsroom filled with talented young reporters. We also have the country’s most robust editing and fact-checking team, finest news photographers and video professionals. We are building India’s most ambitious and energetic news platform. And have just turned three.

At ThePrint, we invest in quality journalists. We pay them fairly. As you may have noticed, we do not flinch from spending whatever it takes to make sure our reporters reach where the story is.

This comes with a sizable cost. For us to continue bringing quality journalism, we need readers like you to pay for it.

If you think we deserve your support, do join us in this endeavour to strengthen fair, free, courageous and questioning journalism. Please click on the link below. Your support will define ThePrint’s future.

Support Our Journalism

Share Your Views

LEAVE A REPLY

Please enter your comment!
Please enter your name here